ACXP
Acurx Pharmaceuticals, Inc.
Next earnings Aug 10, 2026 · consensus $-0.38 EPS
$1.52
▲ 0.00%$1.52▼ -87.40%
over 1Y
L $1.35EODHDH $12.58
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+0.0%
1W+0.7%
1M-23.6%
3M-59.6%
YTD-44.9%
1Y-87.4%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 9 analysts
Buy
Conservative balance sheet (liabilities/equity 0.46x).
Return on equity -151.2% · latest
Acurx Pharmaceuticals, Inc. shows limited reported revenue, and -151.2% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | — | — | — | -$14.1M | -$8.09M |
| Net income | -$12.7M | -$12.1M | -$14.6M | -$14.1M | -$7.97M |
| Diluted EPS | -$1.49 | -$1.12 | -$1.15 | -$17.45 | -$5.32 |
| Net margin | — | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value-$3.22M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-183.6%
FCF yield—
Quality & risk
ROIC (est.)-121.3%
Free cash flow—
Total debt—
Net cash$7.56M
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY-87.0%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
- 10-Q Quarterly report2026-05-11
- S-1 Securities registration2026-05-04
- S-1 Securities registration2026-05-04
- 8-K Material agreement2026-04-16
- 10-K Annual report2026-03-12
- 8-K Officer / director change2026-03-09
- S-1 Securities registration2026-02-02
- S-3/A Shelf registration (potential raise)2025-12-30
- 10-Q Quarterly report2025-11-12
Recent filings
all on EDGAR ↗424B3Filing2026-05-12open ↗424B3Filing2026-05-12open ↗EFFECTFiling2026-05-11open ↗EFFECTFiling2026-05-11open ↗10-QPeriod ending 2026-03-312026-05-11open ↗CORRESPFiling2026-05-07open ↗CORRESPFiling2026-05-07open ↗UPLOADFiling2026-05-07open ↗UPLOADFiling2026-05-07open ↗S-1Filing2026-05-04open ↗S-1Filing2026-05-04open ↗DFiling2026-04-29open ↗
Frequently asked
- Is Acurx Pharmaceuticals, Inc. (ACXP) a buy?
- ACXP currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.46x).
- What is Acurx Pharmaceuticals, Inc.'s quality score?
- ACXP scores 59.15384615384615/100 (grade C) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001736243, latest 10-Q filed 2026-05-11) · EODHD · as of 6/24/2026, 1:12:11 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.